Comparative Analysis of Direct In-Bore MRI-Guided vs Fusion-Guided Prostate Biopsy

Overview

This study compares clinically significant prostate cancer (csPCa) detection rates between direct in-bore MR-guided biopsy (MRGB) and MRI-TRUS fusion-guided biopsy (FGB) in patients with MRI-detected lesions ≥8 mm. Both techniques showed comparable csPCa detection rates, with MRGB being more time-consuming and less accessible than FGB.

Background

Multiparametric MRI (mpMRI) has revolutionized prostate cancer diagnosis by enabling targeted biopsies of suspicious lesions, improving detection of clinically significant prostate cancer (csPCa) compared to systematic TRUS biopsy. Two main targeted biopsy techniques are direct in-bore MR-guided biopsy (MRGB) and MRI-TRUS fusion-guided biopsy (FGB). MRGB offers precise targeting but is resource-intensive, while FGB is more accessible and allows concurrent systematic biopsy. This study aims to compare csPCa detection rates between these two approaches in patients with PI-RADS 4 or 5 lesions ≥8 mm.

Data Highlights

Key Findings

• Both FGB and MRGB targeted PI-RADS 4 or 5 lesions ≥8 mm in patients with prior negative TRUS biopsies.
• FGB was performed by a radiologist without prior prostate biopsy experience, while MRGB was performed by experienced personnel.
• FGB procedure time was significantly shorter (10–20 minutes) compared to MRGB (45–60 minutes).
• Both techniques did not use anesthetics and did not include systematic 10–12 core biopsies.
• csPCa detection was based on Gleason score ≥7, with no significant difference reported between the two methods.
• FGB uses software-assisted fusion with electromagnetic tracking, while MRGB uses direct MR guidance with needle position confirmation after each biopsy.

Clinical Implications

FGB offers a less time-consuming and more accessible alternative to MRGB for targeted biopsy of larger (≥8 mm) suspicious prostate lesions, without compromising csPCa detection rates. Clinicians may consider FGB especially in settings where MR-guided biopsy resources are limited. However, MRGB remains a precise option, particularly for smaller or more challenging lesions not suitable for fusion biopsy.

Conclusion

In patients with MRI-detected prostate lesions ≥8 mm, fusion-guided biopsy provides comparable detection of clinically significant prostate cancer to direct in-bore MR-guided biopsy, with advantages in procedure time and accessibility. These findings support the use of FGB as a practical alternative to MRGB in appropriate clinical contexts.

References

1. European Association of Urology Guidelines -- Prostate Cancer Diagnosis
2. Study Comparing MRGB and FGB Techniques -- 2014-2016 Institutional Data